Extension Study to Evaluate the Safety of Q8003 in Patients With Acute Moderate to Severe Pain

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007
This is a Phase 3 double-blind, multiple dose safety extension study of Q8003 administered at daily doses up to 36 mg morphine/24 mg oxycodone (Q8003 36mg/24mg) over a treatment period of up to 4 weeks. Patients with acute moderate to severe pain who have completed participation in one of the designated QRxPharma, Inc. acute pain lead-in studies will be eligible for this trial.
Epistemonikos ID: 96400b1ab05122b31dc51194d44c79d473663ec7
First added on: May 04, 2024